Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The venue will be the Fairmont Copley Plaza in Boston.

Please contact Julie Powers [email protected] with your interest in attending this exciting program as space is limited.

iwMyeloma 2016

22–24 April 2016 | Fairmont Copley Plaza, Boston

iwMyeloma 2016

22–24 April 2016 | Fairmont Copley Plaza, Boston

The venue will be the Fairmont Copley Plaza in Boston.

Please contact Julie Powers [email protected] with your interest in attending this exciting program as space is limited.

The Cassiopeia trial – assessing daratumumab in the context of stem cell transplantation 2:39
The Cassiopeia trial – assessing daratumumab in the context of stem cell transplantation
Philippe Moreau • 22 Apr 2016
Myeloma 2016: Panel discussion on gene modified T-cells 9:13
Myeloma 2016: Panel discussion on gene modified T-cells
Edward Stadtmauer et al. • 22 Apr 2016
Myeloma 2016: Panel discussion on the environment biology of myeloma 9:33
Myeloma 2016: Panel discussion on the environment biology of myeloma
Dirk Hose et al. • 22 Apr 2016
Myeloma 2016: Panel discussion on the application of genomics studies 10:26
Myeloma 2016: Panel discussion on the application of genomics studies
Leif Bergsagel et al.
Myeloma 2016: Panel discussion on the status of genomics 14:35
Myeloma 2016: Panel discussion on the status of genomics
Chng W. Joo et al.
Myeloma 2016: Panel discussion on in vivo drug screening 12:46
Myeloma 2016: Panel discussion on in vivo drug screening
Caroline Heckman et al.
PET-CT vs MRI in multiple myeloma 1:59
PET-CT vs MRI in multiple myeloma
Philippe Moreau • 22 Apr 2016
How immunomodulatory drugs have reinforced the value of the immune system in multiple myeloma 3:06
How immunomodulatory drugs have reinforced the value of the immune system in multiple myeloma
Jesús San Miguel • 22 Apr 2016
Results of KEYNOTE-023 and pembrolizumab plus pomalidomide trials for multiple myeloma 3:49
Results of KEYNOTE-023 and pembrolizumab plus pomalidomide trials for multiple myeloma
Jesús San Miguel • 22 Apr 2016
Venetoclax for multiple myeloma – mechanism of action and next steps 1:58
Venetoclax for multiple myeloma – mechanism of action and next steps
Lawrence Boise • 22 Apr 2016
Insights into the genomics of multiple myeloma – new drug targets and when to do a genomic analysis 2:37
Insights into the genomics of multiple myeloma – new drug targets and when to do a genomic analysis
Nikhil Munshi • 22 Apr 2016
What role will minimal residual disease testing play in multiple myeloma? 3:58
What role will minimal residual disease testing play in multiple myeloma?
Ola Landgren • 22 Apr 2016
The impact of new drugs and the changing role of transplants in multiple myeloma 3:58
The impact of new drugs and the changing role of transplants in multiple myeloma
Paul Richardson • 22 Apr 2016
Myeloma 2016: Panel discussion on the new treatment paradigm 11:57
Myeloma 2016: Panel discussion on the new treatment paradigm
Gareth Morgan et al.
Myeloma 2016: Panel discussion on novel treatments 13:09
Myeloma 2016: Panel discussion on novel treatments
Keith Stewart et al. • 22 Apr 2016
Mechanism of action of daratumumab 2:03
Mechanism of action of daratumumab
Niels van de Donk • 22 Apr 2016
The content of VJHemOnc is intended for healthcare professionals